Value Investors: 1 Global Cannabis Stock to Buy

As the company’s supply chain grows, Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) continues to expand the company’s portfolio of cannabis products for the existing markets in Canada.

| More on:

Cronos Group (TSX:CRON)(NASDAQ:CRON) is an innovative global cannabinoid (CBD) company with international production and distribution across five continents. Cronos Group builds disruptive intellectual property by advancing cannabis research, technology, and product development. The company is in the process of building an iconic brand portfolio that responsibly elevates the consumer experience.

In the United States, Cronos markets and distributes solely U.S. hemp-derived supplements and cosmetic products through e-commerce, retail and hospitality channels. In Canada, the company sells a variety of cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under the company’s wellness platform. In addition, dried cannabis and cannabis oils are currently exported for sale to Australia, Germany, and Israel.

Reputable wellness and adult-use brands

The company currently distribute products for the Canadian and non-U.S. international medical cannabis markets. Through the company’s global wellness platform, Cronos produces high-quality cannabis and cannabis products and is focused on building and shaping the global cannabis wellness market and promoting a holistic approach to wellness. The brand’s goal is to improve the lives of others one client at a time.

The company’s premium positioned brand is focused on creating crafted experiences. Cronos’s brands are geared towards a wide range of consumers who are looking for entertainment and fun ways to enhance activities. Cronos also owns lighthearted and playful brands that are focused on offering products that bring friends together and make experiences more enjoyable.

High-quality products

The company develops a preeminent U.S. hemp-derived CBD brand in the U.S. for the adult consumer goods market. Cronos focuses on high-quality U.S. hemp-derived personal care products that are distributed online to approximately 900 premium stores and retail channels.

Cronos recently launched a U.S. hemp-derived CBD brand in the United States. The product stems from the belief that well-being can lead to a better world that’s full of positivity and possibility. It is a belief that extends beyond the products and into everything the brand seeks to do and stand for. The brand intends to distribute products through the mass market focused retail channel in the U.S. in the future.

Diversified global network

Cronos has developed a diversified global sales and distribution network by leveraging established partners for the company’s scale, sales force and market expertise. The company has also built a distribution footprint in Canada through the direct-to-client medical market and the adult-use market, as well as a distribution footprint for hemp-derived consumer products in the U.S. through e-commerce, retail, and hospitality channels.

The company plans to use resources to capitalize on market demand and to further create and scale U.S. hemp-derived consumer products and brands. Cronos intends to access the U.S. mass market focused retail channel in the future. The company currently sells dried cannabis and cannabis extracts directly to clients through Cronos’s wellness platform. Clients are typically sourced through physician and clinic referrals or word-of-mouth recommendations from existing clients.

As the company’s supply chain grows, Cronos continues to expand the company’s portfolio of cannabis products for the existing markets in Canada.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »